[go: up one dir, main page]

MX2018006738A - Factor viii con propiedades de semivida extendida y union reducida al ligando. - Google Patents

Factor viii con propiedades de semivida extendida y union reducida al ligando.

Info

Publication number
MX2018006738A
MX2018006738A MX2018006738A MX2018006738A MX2018006738A MX 2018006738 A MX2018006738 A MX 2018006738A MX 2018006738 A MX2018006738 A MX 2018006738A MX 2018006738 A MX2018006738 A MX 2018006738A MX 2018006738 A MX2018006738 A MX 2018006738A
Authority
MX
Mexico
Prior art keywords
life
factor viii
binding properties
extended half
reduced ligand
Prior art date
Application number
MX2018006738A
Other languages
English (en)
Inventor
Turecek Peter
Siekmann Juergen
Schrenk Gerald
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2018006738A publication Critical patent/MX2018006738A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a materiales y métodos de conjugar un polímero soluble en agua a un resto de carbohidrato oxidado de una proteína terapéutica que comprende poner en contacto el resto de carbohidrato oxidado con un polímero soluble en agua activado en condiciones que permiten la conjugación. Más específicamente, la presente invención se refiere a un factor VIII recombinante modificado (FVIII) con de propiedades de semivida extendida y unión al ligando reducida.
MX2018006738A 2015-12-03 2016-12-05 Factor viii con propiedades de semivida extendida y union reducida al ligando. MX2018006738A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262674P 2015-12-03 2015-12-03
PCT/US2016/064979 WO2017096383A1 (en) 2015-12-03 2016-12-05 Factor viii with extended half-life and reduced ligand-binding properties

Publications (1)

Publication Number Publication Date
MX2018006738A true MX2018006738A (es) 2018-09-21

Family

ID=57614469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006738A MX2018006738A (es) 2015-12-03 2016-12-05 Factor viii con propiedades de semivida extendida y union reducida al ligando.

Country Status (16)

Country Link
US (2) US20170349644A1 (es)
EP (1) EP3383895A1 (es)
JP (1) JP2019510022A (es)
KR (1) KR20180088727A (es)
CN (1) CN108884146A (es)
AR (1) AR106914A1 (es)
AU (1) AU2016362606A1 (es)
BR (1) BR112018011259A2 (es)
CA (1) CA3007364A1 (es)
EA (1) EA201891333A1 (es)
IL (1) IL259760A (es)
MX (1) MX2018006738A (es)
PH (1) PH12018501174A1 (es)
SG (2) SG11201804666QA (es)
TW (1) TW201731869A (es)
WO (1) WO2017096383A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20170349644A1 (en) * 2015-12-03 2017-12-07 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
CA2349468C (en) 1998-11-10 2013-07-09 Baxter Aktiengesellschaft Factor viii polypeptide having factor viii:c activity
ATE313554T1 (de) 2000-05-16 2006-01-15 Lipoxen Technologies Ltd Derivatisierung von proteinen in wässrigem lösungsmittel
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
US20080206182A1 (en) 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
CN101870729A (zh) * 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101237884B1 (ko) 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
ES2593318T3 (es) 2004-08-12 2016-12-07 Lipoxen Technologies Limited Derivados de ácido siálico
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
EP2257311B1 (en) * 2008-02-27 2014-04-16 Novo Nordisk A/S Conjugated factor viii molecules
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2595442C2 (ru) * 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US9062299B2 (en) * 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
EP3505186B1 (en) * 2010-07-30 2022-01-12 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
CN104519897A (zh) * 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
US20170349644A1 (en) * 2015-12-03 2017-12-07 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties

Also Published As

Publication number Publication date
US20190240295A1 (en) 2019-08-08
TW201731869A (zh) 2017-09-16
SG11201804666QA (en) 2018-06-28
BR112018011259A2 (pt) 2018-11-21
IL259760A (en) 2018-07-31
CA3007364A1 (en) 2017-06-08
AR106914A1 (es) 2018-02-28
KR20180088727A (ko) 2018-08-06
EP3383895A1 (en) 2018-10-10
EA201891333A1 (ru) 2018-12-28
AU2016362606A1 (en) 2018-06-28
JP2019510022A (ja) 2019-04-11
WO2017096383A1 (en) 2017-06-08
US20170349644A1 (en) 2017-12-07
SG10202004031WA (en) 2020-05-28
PH12018501174A1 (en) 2019-01-21
CN108884146A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
PH12018500285A1 (en) Bridge linkers for conjugation of a cell-binding molecule
PH12016501411A1 (en) Bifunctional cytotoxic agents
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018011204A (es) Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso.
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
HK1253507A1 (zh) 抗 ror1 抗体
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
EA201890417A1 (ru) Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
MX371187B (es) Péptidos terapéuticos.
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EP4372002A3 (en) Proximity-based sortase-mediated protein purification and ligation
MX375441B (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
MX2018001825A (es) Variantes y conjugados de albumina.
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
SE542188C2 (en) Supports for membrane enhanced peptide synthesis
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
PH12017501930A1 (en) Calicheamicin contructs and methods of use
PH12018501174A1 (en) Factor viii with extended half-life and reduced ligand-binding properties
MX373193B (es) Conjugados de hemoglobina óxido de polialquileno valerato.
MX2016010229A (es) Conjugados del factor vii.
IN2014CH00390A (es)